FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
SINGAPORE (Reuters) – Singapore’s Health Sciences Authority said on Wednesday it granted conditional approval for Gilead Sciences Inc’s antiviral drug remdesivir for the treatment of some patients with COVID-19 infection.
South Korea, Japan, India and the United States have also approved the drug for emergency use.
Reporting by Aradhana Aravindan and John Geddie in Singapore, editing by Louise Heavens